Medicinal Potential of Isoflavonoids: Polyphenols That May Cure Diabetes

In recent years, there is emerging evidence that isoflavonoids, either dietary or obtained from traditional medicinal plants, could play an important role as a supplementary drug in the management of type 2 diabetes mellitus (T2DM) due to their reported pronounced biological effects in relation to multiple metabolic factors associated with diabetes. Hence, in this regard, we have comprehensively reviewed the potential biological effects of isoflavonoids, particularly biochanin A, genistein, daidzein, glycitein, and formononetin on metabolic disorders and long-term complications induced by T2DM in order to understand whether they can be future candidates as a safe antidiabetic agent. Based on in-depth in vitro and in vivo studies evaluations, isoflavonoids have been found to activate gene expression through the stimulation of peroxisome proliferator-activated receptors (PPARs) (α, γ), modulate carbohydrate metabolism, regulate hyperglycemia, induce dyslipidemia, lessen insulin resistance, and modify adipocyte differentiation and tissue metabolism. Moreover, these natural compounds have also been found to attenuate oxidative stress through the oxidative signaling process and inflammatory mechanism. Hence, isoflavonoids have been envisioned to be able to prevent and slow down the progression of long-term diabetes complications including cardiovascular disease, nephropathy, neuropathy, and retinopathy. Further thoroughgoing investigations in human clinical studies are strongly recommended to obtain the optimum and specific dose and regimen required for supplementation with isoflavonoids and derivatives in diabetic patients.     

具有高安全性和有效性的Ⅱ期两阶段临床试验

Ⅱ期临床试验的主要目的是对药物治疗的安全性和有效性进行评估.针对具有高安全性的Ⅱ期两阶段临床试验,给出小样本量下关于安全性和有效性的精确检验方法,并证明最大Ⅰ类错误概率与Ⅱ类错误概率分别在原假设和备择假设的边界处达到.在期望样本量最小原则下,给出最优两阶段设计的构造方法和常用设计表,供实际应用选用.     

Study of nucleon-nucleon and alphanucleon elastic scattering by the Manning-Rosen potential

Although often used in molecular dynamics, in this work the Manning–Rosen potential is parameterized to compute the scattering phase shifts for the nucleon–nucleon and the alpha-nucleon systems by exploiting the standard phase function method. We obtain excellent agreement in phase shifts with the more sophisticated calculations up to partial waves ${\ell }=2.$     

A distributionally robust area under curve maximization model

Area under ROC curve (AUC) is a performance measure for classification models. We propose new distributionally robust AUC models (DR-AUC) that rely on the Kantorovich metric and approximate AUC with the hinge loss function, and derive convex reformulations using duality. The DR-AUC models outperform deterministic AUC and support vector machine models and have superior worst-case out-of-sample performance, thereby showing their robustness. The results are encouraging since the numerical experiments are conducted with small-size training sets conducive to low out-of-sample performance.     

Evaluating the potential of vaccine-induced type replacement for high-risk human papillomaviruses

Persistent infection with human papillomavirus (HPV) is the main cause of cervical cancer. Current HPV vaccines protect against both HPV-16 and -18, which are known to cause approximately 70% of cervical cancer cases worldwide. These vaccines have shown to be highly effective in preventing infection by their targeted types. However, there is a broad diversity of HPV types not targeted by the vaccines, and there is controversy about a possible increase in the prevalence of these non-targeted types after a vaccination program. Here, we propose a within-host metapopulation model to study the possibility of vaccine-induced type replacement for oncogenic types. It is generally believed that the theoretical possibility of type replacement strongly depends on the existence of natural type competition mechanisms. Nevertheless, our results suggest that type replacement is viable at the within-host level if the degree of cross-protection induced by the vaccine is low, even if there is no underlying competition among HPV types. Consequently, the impact of current HPV vaccines at both the immunological and epidemiological levels rely upon the level of cross-protection.